Association between the tissue accumulation of advanced glycation end products and exercise capacity in cardiac rehabilitation patients.
Advanced glycation end products
Cardiac rehabilitation
Exercise tolerance
Skin autofluorescence
Journal
BMC cardiovascular disorders
ISSN: 1471-2261
Titre abrégé: BMC Cardiovasc Disord
Pays: England
ID NLM: 100968539
Informations de publication
Date de publication:
23 04 2020
23 04 2020
Historique:
received:
08
11
2019
accepted:
14
04
2020
entrez:
25
4
2020
pubmed:
25
4
2020
medline:
25
11
2020
Statut:
epublish
Résumé
Advanced glycation end products (AGEs) are associated with aging, diabetes mellitus (DM), and other chronic diseases. Recently, the accumulation of AGEs can be evaluated by skin autofluorescence (SAF). However, the relationship between SAF levels and exercise capacity in patients with cardiovascular disease (CVD) remains unclear. This study aimed to investigate the association between the tissue accumulation of AGEs and clinical characteristics, including exercise capacity, in patients with CVD. We enrolled 319 consecutive CVD patients aged ≥40 years who underwent early phase II cardiac rehabilitation (CR) at our university hospital between November 2015 and September 2017. Patient background, clinical data, and the accumulation of AGEs assessed by SAF were recorded at the beginning of CR. Characteristics were compared between two patient groups divided according to the median SAF level (High SAF and Low SAF). The High SAF group was significantly older and exhibited a higher prevalence of DM than the Low SAF group. The sex ratio did not differ between the two groups. AGE levels showed significant negative correlations with peak oxygen uptake and ventilator efficiency (both P < 0.0001). Exercise capacity was significantly lower in the high SAF group than in the low SAF group, regardless of the presence or absence of DM (P < 0.05). A multivariate logistic regression analysis showed that SAF level was an independent factor associated with reduced exercise capacity (odds ratio 2.10; 95% confidence interval 1.13-4.05; P = 0.02). High levels of tissue accumulated AGEs, as assessed by SAF, were significantly and independently associated with reduced exercise capacity. These data suggest that measuring the tissue accumulation of AGEs may be useful in patients who have undergone CR, irrespective of whether they have DM.
Sections du résumé
BACKGROUND
Advanced glycation end products (AGEs) are associated with aging, diabetes mellitus (DM), and other chronic diseases. Recently, the accumulation of AGEs can be evaluated by skin autofluorescence (SAF). However, the relationship between SAF levels and exercise capacity in patients with cardiovascular disease (CVD) remains unclear. This study aimed to investigate the association between the tissue accumulation of AGEs and clinical characteristics, including exercise capacity, in patients with CVD.
METHODS
We enrolled 319 consecutive CVD patients aged ≥40 years who underwent early phase II cardiac rehabilitation (CR) at our university hospital between November 2015 and September 2017. Patient background, clinical data, and the accumulation of AGEs assessed by SAF were recorded at the beginning of CR. Characteristics were compared between two patient groups divided according to the median SAF level (High SAF and Low SAF).
RESULTS
The High SAF group was significantly older and exhibited a higher prevalence of DM than the Low SAF group. The sex ratio did not differ between the two groups. AGE levels showed significant negative correlations with peak oxygen uptake and ventilator efficiency (both P < 0.0001). Exercise capacity was significantly lower in the high SAF group than in the low SAF group, regardless of the presence or absence of DM (P < 0.05). A multivariate logistic regression analysis showed that SAF level was an independent factor associated with reduced exercise capacity (odds ratio 2.10; 95% confidence interval 1.13-4.05; P = 0.02).
CONCLUSION
High levels of tissue accumulated AGEs, as assessed by SAF, were significantly and independently associated with reduced exercise capacity. These data suggest that measuring the tissue accumulation of AGEs may be useful in patients who have undergone CR, irrespective of whether they have DM.
Identifiants
pubmed: 32326893
doi: 10.1186/s12872-020-01484-3
pii: 10.1186/s12872-020-01484-3
pmc: PMC7178950
doi:
Substances chimiques
Biomarkers
0
Glycation End Products, Advanced
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
195Subventions
Organisme : Japan Society for the Promotion of Science
ID : 17K01470
Pays : International
Références
Diabetes Technol Ther. 2011 Feb;13(2):165-70
pubmed: 21284484
Redox Biol. 2017 Apr;11:637-645
pubmed: 28131082
Clin Cardiol. 2015 Apr;38(4):222-9
pubmed: 25707582
Diab Vasc Dis Res. 2013 May;10(3):222-38
pubmed: 23162060
N Engl J Med. 2002 Mar 14;346(11):793-801
pubmed: 11893790
Geriatr Gerontol Int. 2017 May;17(5):785-790
pubmed: 27119258
J Am Coll Cardiol. 1998 Mar 1;31(3):577-82
pubmed: 9502638
Curr Diab Rep. 2017 Aug;17(8):63
pubmed: 28695383
Geriatr Gerontol Int. 2019 Apr;19(4):287-292
pubmed: 30793829
World J Cardiol. 2012 Apr 26;4(4):90-102
pubmed: 22558488
Eur J Heart Fail. 2011 Jan;13(1):76-82
pubmed: 20861128
Circulation. 2002 Dec 10;106(24):3079-84
pubmed: 12473555
J Am Coll Cardiol. 1991 Apr;17(5):1065-72
pubmed: 2007704
Diabetes Care. 2005 Jul;28(7):1643-8
pubmed: 15983314
J Clin Endocrinol Metab. 2009 Oct;94(10):3687-95
pubmed: 19584191
Diabetes Res Clin Pract. 2000 Oct;50(2):109-15
pubmed: 10960721
J Cardiol. 2011 Sep;58(2):173-80
pubmed: 21741799
Diabetologia. 2004 Jul;47(7):1324-1330
pubmed: 15243705
Nature. 2001 Dec 13;414(6865):813-20
pubmed: 11742414
J Am Heart Assoc. 2018 Sep 18;7(18):e009833
pubmed: 30371199
Int J Angiol. 2015 Jun;24(2):75-80
pubmed: 26060376
Rev Endocr Metab Disord. 2013 Mar;14(1):77-86
pubmed: 23299658
Dermatoendocrinol. 2012 Jul 1;4(3):259-70
pubmed: 23467327
Circ J. 2018 Dec 25;83(1):101-109
pubmed: 30404973
J Cardiol. 2013 Mar;61(3):216-21
pubmed: 23332345
J Am Coll Cardiol. 1994 Feb;23(2):358-63
pubmed: 8294687
Cardiovasc Ther. 2012 Feb;30(1):42-8
pubmed: 20626403
Circulation. 1998 Jul 28;98(4):369-74
pubmed: 9711943
Eur J Heart Fail. 2011 Aug;13(8):899-908
pubmed: 21669961
Diabetologia. 2019 Feb;62(2):269-280
pubmed: 30460578
JAMA. 2009 Jan 21;301(3):286-94
pubmed: 19155455
Circulation. 1991 Mar;83(3):778-86
pubmed: 1999029
Oxid Med Cell Longev. 2015;2015:534873
pubmed: 25878764
J Clin Endocrinol Metab. 2010 Feb;95(2):513-21
pubmed: 19915016
Diabetes Care. 2007 Oct;30(10):2679-84
pubmed: 17644623
Eur J Appl Physiol. 2010 Jan;108(1):191-5
pubmed: 19756703
Diabetes Care. 2006 Dec;29(12):2654-9
pubmed: 17130200
J Gerontol A Biol Sci Med Sci. 2009 Jan;64(1):132-7
pubmed: 19182228
Diabet Med. 2019 May;36(5):620-625
pubmed: 30706538
J Am Coll Cardiol. 2002 May 15;39(10):1615-22
pubmed: 12020488
Diabetes. 2006 Jun;55(6):1813-8
pubmed: 16731847
Diabetologia. 2004 Oct;47(10):1727-34
pubmed: 15490108
Opt Express. 2010 Jul 5;18(14):14416-29
pubmed: 20639927
Am J Kidney Dis. 2009 Jun;53(6):982-92
pubmed: 19339088
Int J Cardiol. 2015 Apr 15;185:263-8
pubmed: 25814214
Curr Diab Rep. 2014 Jan;14(1):453
pubmed: 24292971
J Vasc Surg. 2013 Mar;57(3):728-33
pubmed: 23044259
JAMA. 2002 Oct 2;288(13):1622-31
pubmed: 12350193
Diabetes Technol Ther. 2006 Oct;8(5):523-35
pubmed: 17037967
Ann Intern Med. 2000 Apr 18;132(8):605-11
pubmed: 10766678
Sports Med. 2003;33(12):877-88
pubmed: 12974656
Endocrinol Metab Clin North Am. 2014 Mar;43(1):41-57
pubmed: 24582091